Dimethylnitrosamine (DMN) has been characterized as a potent hepatotoxin, carcinogen
and mutagen. As described below, immunotoxicity should be added to its profile of activity. …

Objective Treatment of rheumatoid arthritis and other autoimmune disorders with anti–tumor
necrosis factor (anti‐TNF) agents is associated with an increased risk of reactivation of …

OBJECTIVE: The immunogenicity of abatacept, a selective costimulation modulator, administered
intravenously, was assessed across Phase II and III trials in patients with rheumatoid …

… Gilbert, Jill Giles-Komar, Elizabeth R Gore, Peter Griem, Ina Hagelschuer, Helen G. Haggerty,
Andrew Hall, S. Hanneken, Kenneth L Hastings, Arie H Havelaar, Eckhart Heisler, Ricki M …

Immunotoxins have shown promise as antitumor agents in clinical trials. However, they have
not become part of standard cancer therapy because of factors that include their inherent …

BMS-986251 is a retinoid-related orphan receptor γt (RORγt) inverse agonist that was in
development for the treatment of autoimmune diseases. RORγt is a nuclear hormone receptor …

Observational and clinical studies have associated increased cancer risks with primary or
acquired immunodeficiencies, autoimmunity, and use of immunotherapies to treat chronic …

The development of novel therapies that can harnass the immune system to eradicate cancer
is an area of intensive research. Several new biopharmaceuticals that target the immune …

Protein therapeutics represent a rapidly growing proportion of new medicines being developed
by the pharmaceutical industry. As with any new drug, an Occupational Exposure Limit (…

Evaluation of the immunotoxicity potential of some pharmaceuticals, including immunomodulatory
chemicals and biologics, cannot be limited to testing in rodents. Thus, immune …